A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

NCT05240131 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: GB1211
DRUG: Placebo
DRUG: Atezolizumab

Sponsor

Galecto Biotech AB

Collaborators

[object Object]
[object Object]